Loading...

RAPP RAPPORT THERAPEUTICS INC Management Changes 8-K Filing

RPPR

RPP

RAPPORT THERAPEUTICS INC

(RAPP)

2025 8-K

Financial Results Update

Seizure Reduction Results

Financial Results Update

Stock Offering Announcement

Program Expansion

Financial Results Announced

Stock Offering Update

Sales Agreement Termination

Positive Clinical Results

Financial Statements

Product Expansion

Financial Statements

Financial Results

Management Update

Financial Results

External Links:

On March 3, 2025, Rapport Therapeutics announced the appointment of Jeffrey Sevigny as Chief Medical Officer and provided updates on its Phase 2a trials for RAP-219 in refractory focal epilepsy and bipolar mania, expecting topline results in Q3 2025 and Q1 2027 respectively.

AI Assistant

RAPPORT THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.